XLRN - Acceleron Pharma holder Farallon Capital is said not to support sale to Merck

Acceleron Pharma (NASDAQ:XLRN) holder Farallon Capital Management doesn't support Merck's $180/share acquisition of the company. Farallon, which is a top-10 Acceleron (XLRN) holder with a more than 4% stake, told Bloomberg in email that the company doesn't support terms of its sale to Merck (NYSE:MRK). Farallon joins other holders including Darwin Global Management and Holocene Advisors who also have said they won't tender their shares for the deal. Last week, Merck withdraws Acceleron filing to allow FTC more review time. Last month, Bristol plans to tender Acceleron shares as Merck seeks acquisition - Bloomberg.

For further details see:

Acceleron Pharma holder Farallon Capital is said not to support sale to Merck